A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times
Source: A New Drug Scourge: Deaths Involving Meth Are Rising Fast - The New York Times
read moreUS addiction crisis far from over: Lawmakers raise new cocaine, meth concerns | S&P Global Market Intelligence
Source: US addiction crisis far from over: Lawmakers raise new cocaine, meth concerns | S&P Global Market Intelligence
read moreNumber of babies born exposed to drugs displays meth problem
Source: Number of babies born exposed to drugs displays meth problem
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times
Source: A New Drug Scourge: Deaths Involving Meth Are Rising Fast - The New York Times
read moreUS addiction crisis far from over: Lawmakers raise new cocaine, meth concerns | S&P Global Market Intelligence
Source: US addiction crisis far from over: Lawmakers raise new cocaine, meth concerns | S&P Global Market Intelligence
read moreNumber of babies born exposed to drugs displays meth problem
Source: Number of babies born exposed to drugs displays meth problem
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.